BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/23/2026 6:25:02 AM | Browse: 1 | Download: 0
 |
Received |
|
2025-12-18 10:48 |
|
Peer-Review Started |
|
2025-12-18 10:48 |
|
First Decision by Editorial Office Director |
|
2026-01-15 07:38 |
|
Return for Revision |
|
2026-01-15 07:38 |
|
Revised |
|
2026-01-21 13:50 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-06 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-06 08:20 |
|
Articles in Press |
|
2026-03-06 08:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-20 06:27 |
|
Publish the Manuscript Online |
|
2026-07-23 06:25 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Correspondence |
| Article Title |
Advancing the clinical translation of triptolide and quercetin in hepatocellular carcinoma: A commentary on dual JAK-STAT/mTOR inhibition
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hua Liu, Wei-Yi Jiang and Fei-Fei Mao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fei-Fei Mao, Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, No. 227 Chongqing South Road, Shanghai 200086, China. maofeifei01@126.com |
| Key Words |
Hepatocellular carcinoma; Combination chemotherapy; Triptolide; Quercetin; Janus kinase-signal transducer and activator of transcription pathway; Mammalian target of rapamycin pathway |
| Core Tip |
Tong et al provide a robust preclinical foundation for the combined triptolide and quercetin therapy for hepatocellular carcinoma. They demonstrate synergistic anti-tumor activity through a multi-pathway mechanism where both compounds bind to key proteins like Janus kinase 1, signal transducer and activator of transcription 3, phosphoinositide 3-kinases, and mammalian target of rapamycin, disrupting carcinogenic signaling. This research adds to the growing body of work on natural product-based cancer therapies. To advance this promising start, future investigations using immunocompetent models, detailed pharmacokinetic studies, and deeper mechanistic validation are essential. Such efforts may translate these findings into a viable clinical strategy, aligning with the broader push toward precision medicine in oncology. |
| Publish Date |
2026-07-23 06:25 |
| Citation |
Liu H, Jiang WY, Mao FF. Advancing the clinical translation of triptolide and quercetin in hepatocellular carcinoma: A commentary on dual JAK-STAT/mTOR inhibition. World J Gastroenterol 2026; 32(30): 117813
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i30/117813.htm |
| DOI |
https://doi.org/10.3748/wjg.117813 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
